Literature DB >> 2408809

Myocardial ischemia induced by prostacyclin and iloprost.

R Bugiardini, M Galvani, D Ferrini, C Gridelli, D Tollemeto, L Mari, P Puddu, S Lenzi.   

Abstract

Vasodilators of resistive vessels may induce ischemia in patients with coronary artery disease. To evaluate this possibility during prostacyclin (PGI2; scalar doses up to 10 ng/kg/min) and prostacyclin analog (iloprost; scalar doses up to 6 ng/kg/min) infusions, we studied 33 patients with angina pectoris and proved coronary artery disease. Patients were also submitted to dipyridamole (0.15 mg/kg/min for 4 minutes) and exercise stress testing (starting at 25 W and increasing 25 W every 2 minutes). In a preliminary study the hemodynamic and side effects of iloprost were studied in seven healthy subjects. At an iloprost dose of 4 to 6 ng/kg/min, these subjects had a significant decrease in mean arterial pressure and total peripheral and pulmonary vascular resistances. Side effects were limited to facial flushing and slight headache and were readily reversible. PGI2 induced typical chest pain and significant ST segment depression in six patients with severe coronary artery disease (three with left main and three with triple vessel disease) and poor exercise tolerance (means +/- SD = 362 +/- 99 seconds). All six patients had had angina during the dipyridamole infusion. Similar findings were observed after iloprost infusion in four of these. Aminophylline (125 mg iv) completely relieved chest pain. Although the rate-pressure products occasionally rose during PGI2 and iloprost infusions, there were no significant changes between ischemic (11.3 +/- 2.3 and 10.6 +/- 1.4 X 10(-3) U) and preischemic (10.8 +/- 1.5 and 10.7 +/- 1.4 X 10(-3) U) rates of infusion. Our data indicate that PGI2 and iloprost may induce ischemia independently of changes in oxygen demand, and suggest that these drugs dilate small coronary vessels. This may result in decreased subendocardial perfusion pressure and/or "coronary steal."

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408809     DOI: 10.1038/clpt.1985.142

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis.

Authors:  F Guideri; M Acampa; S Rechichi; P L Capecchi; P E Lazzerini; M Galeazzi; A Auteri; F Laghi-Pasini
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

2.  Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.

Authors:  H Darius; V Hossmann; K Schrör
Journal:  Klin Wochenschr       Date:  1986-06-16

Review 3.  Compression of adjacent anatomical structures by pulmonary artery dilation.

Authors:  Wael Dakkak; Adriano R Tonelli
Journal:  Postgrad Med       Date:  2016-03-07       Impact factor: 3.840

Review 4.  Functional and structural adaptations of the coronary macro- and microvasculature to regular aerobic exercise by activation of physiological, cellular, and molecular mechanisms: ESC Working Group on Coronary Pathophysiology and Microcirculation position paper.

Authors:  Akos Koller; M Harold Laughlin; Edina Cenko; Cor de Wit; Kálmán Tóth; Raffaele Bugiardini; Danijela Trifunovits; Marija Vavlukis; Olivia Manfrini; Adam Lelbach; Gabriella Dornyei; Teresa Padro; Lina Badimon; Dimitris Tousoulis; Stephan Gielen; Dirk J Duncker
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 13.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.